MX355325B - Quinazolincarboxamida azetidinas. - Google Patents

Quinazolincarboxamida azetidinas.

Info

Publication number
MX355325B
MX355325B MX2013005751A MX2013005751A MX355325B MX 355325 B MX355325 B MX 355325B MX 2013005751 A MX2013005751 A MX 2013005751A MX 2013005751 A MX2013005751 A MX 2013005751A MX 355325 B MX355325 B MX 355325B
Authority
MX
Mexico
Prior art keywords
azetidines
quinazoline carboxamide
quinazoline
carboxamide
cancer
Prior art date
Application number
MX2013005751A
Other languages
English (en)
Other versions
MX2013005751A (es
Inventor
Bankston Donald
R Huck Bayard
Goutopoulos Andreas
Neagu Constantin
Jones Reinaldo
Xiao Yufang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2013005751A publication Critical patent/MX2013005751A/es
Publication of MX355325B publication Critical patent/MX355325B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención proporciona nuevos compuestos de quinazolincarboxamida azetidina de acuerdo con la fórmula (I) y su uso para el tratamiento de enfermedades hiperproliferativas tales como el cáncer.
MX2013005751A 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas. MX355325B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41713110P 2010-11-24 2010-11-24
PCT/EP2011/005691 WO2012069146A1 (en) 2010-11-24 2011-11-11 Quinazoline carboxamide azetidines

Publications (2)

Publication Number Publication Date
MX2013005751A MX2013005751A (es) 2013-08-01
MX355325B true MX355325B (es) 2018-04-16

Family

ID=45001695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005751A MX355325B (es) 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas.

Country Status (31)

Country Link
US (1) US8946247B2 (es)
EP (1) EP2643313B9 (es)
JP (1) JP5897590B2 (es)
KR (1) KR101894116B1 (es)
CN (1) CN103228649B (es)
AR (1) AR093725A1 (es)
AU (1) AU2011334173B2 (es)
BR (1) BR112013012488B1 (es)
CA (1) CA2818706C (es)
CL (1) CL2013001459A1 (es)
CO (1) CO6721019A2 (es)
DK (1) DK2643313T3 (es)
EA (1) EA023821B1 (es)
ES (1) ES2594404T3 (es)
HK (1) HK1188444A1 (es)
HR (1) HRP20161183T1 (es)
HU (1) HUE028967T2 (es)
IL (1) IL226233A (es)
LT (1) LT2643313T (es)
MX (1) MX355325B (es)
MY (1) MY186456A (es)
NZ (1) NZ612224A (es)
PE (1) PE20140966A1 (es)
PL (1) PL2643313T3 (es)
PT (1) PT2643313T (es)
RS (1) RS55204B1 (es)
SG (1) SG190318A1 (es)
SI (1) SI2643313T1 (es)
UA (1) UA112167C2 (es)
WO (1) WO2012069146A1 (es)
ZA (1) ZA201304637B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2755958T (lt) 2011-09-12 2017-11-10 Merck Patent Gmbh Aminopirimidino dariniai, skirti naudoti kaip kinazės aktyvumo moduliatoriai
SI2755965T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Novi imidazolni amidi kot modulatorji kinazne aktivnosti
EP2920178B1 (en) 2012-11-16 2016-12-21 Merck Patent GmbH Novel heterocyclic derivatives as modulators of kinase activity (p70s6 and akt)
JP6280130B2 (ja) 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
BR112015011974A8 (pt) * 2012-11-29 2019-10-08 Merck Patent Gmbh derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
EP2970201B1 (en) 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
BR112016020135A8 (pt) * 2014-04-03 2021-07-06 Merck Patent Gmbh mistura de composto, seus usos, composição farmacêutica, e conjunto (kit)
NZ731770A (en) * 2014-12-11 2023-05-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
EP3416641A1 (en) * 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
US20200164068A1 (en) * 2016-02-16 2020-05-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
JP2021515767A (ja) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Ｅｒｋ５阻害剤の同定及び使用
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2007507531A (ja) 2003-09-30 2007-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP4800216B2 (ja) 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
DE602004024115D1 (de) 2003-12-09 2009-12-24 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
DE102007032739A1 (de) * 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DK2396307T3 (en) * 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012016001A1 (en) * 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides

Also Published As

Publication number Publication date
SG190318A1 (en) 2013-06-28
CN103228649A (zh) 2013-07-31
IL226233A0 (en) 2013-07-31
US20130252942A1 (en) 2013-09-26
EP2643313B1 (en) 2016-06-29
HRP20161183T1 (hr) 2016-11-04
NZ612224A (en) 2015-01-30
BR112013012488A2 (pt) 2016-07-19
PL2643313T3 (pl) 2017-03-31
AR093725A1 (es) 2015-06-24
EA023821B1 (ru) 2016-07-29
CA2818706C (en) 2019-07-23
SI2643313T1 (sl) 2016-11-30
EP2643313A1 (en) 2013-10-02
DK2643313T3 (en) 2016-10-24
EA201300610A1 (ru) 2013-12-30
JP2013544257A (ja) 2013-12-12
MX2013005751A (es) 2013-08-01
KR101894116B1 (ko) 2018-08-31
MY186456A (en) 2021-07-22
AU2011334173A1 (en) 2013-05-02
EP2643313B9 (en) 2017-02-22
KR20130130753A (ko) 2013-12-02
JP5897590B2 (ja) 2016-03-30
UA112167C2 (uk) 2016-08-10
AU2011334173B2 (en) 2015-07-16
PT2643313T (pt) 2016-10-11
CL2013001459A1 (es) 2013-12-27
HUE028967T2 (en) 2017-01-30
ES2594404T3 (es) 2016-12-20
LT2643313T (lt) 2016-10-25
CO6721019A2 (es) 2013-07-31
CN103228649B (zh) 2015-11-25
HK1188444A1 (zh) 2014-05-02
CA2818706A1 (en) 2012-05-31
PE20140966A1 (es) 2014-08-06
ZA201304637B (en) 2014-03-26
US8946247B2 (en) 2015-02-03
RS55204B1 (sr) 2017-01-31
BR112013012488B1 (pt) 2021-08-31
WO2012069146A1 (en) 2012-05-31
IL226233A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
MX355325B (es) Quinazolincarboxamida azetidinas.
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
NZ700928A (en) Dna-pk inhibitors
WO2012013282A8 (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
IN2012DN03883A (es)
MY162933A (en) Chemical compounds
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MX343706B (es) Derivados heterocíclicos novedosos.
IN2012DN02081A (es)
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
EP2670763A1 (en) Certain chemical entities, compositions, and methods
MY151342A (en) Phenylamino isonicotinamide compounds
MX346095B (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX336294B (es) Inhibidores de iap.
WO2014086453A8 (en) Azaheterobicyclic compounds
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.

Legal Events

Date Code Title Description
FG Grant or registration